Bioventix PLC (AIM:BVXP)
2,050.00
+150.00 (7.89%)
Oct 31, 2025, 4:41 PM GMT+1
Bioventix Company Description
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide.
The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; Pyrene 1-hydroxypyrene glucuronide (HOP-G) ELISA kit to monitor human exposure to industrial pollutants; and Pyrene (HOP-G) lateral flow kits for monitoring of at-risk individuals without laboratory equipment.
It also provides contract SMAs services; and industrial and environmental biomonitoring platform, which reduces the time between sampling and results.
Bioventix PLC was incorporated in 2003 and is based in Farnham, United Kingdom.
Bioventix PLC
| Country | United Kingdom |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Peter Harrison |
Contact Details
Address: 7 Romans Business Park Farnham, GU9 7SX United Kingdom | |
| Phone | 44 12 5272 8001 |
| Website | bioventix.com |
Stock Details
| Ticker Symbol | BVXP |
| Exchange | London Stock Exchange AIM |
| Fiscal Year | July - June |
| Reporting Currency | GBP |
| ISIN Number | GB00B4QVDF07 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Peter Harrison | Chief Executive Officer |
| Bruce Edward Hiscock | Chief Financial Officer |